A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences

Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions

(2017) Gregory S. Calip et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line

(2017) A Svedbom et al.   Patient Preference and Adherence

Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria

(2016) M Inzinger et al.   ACTA DERMATO-VENEREOLOGICA

The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study

(2016) Yuan An et al.   CLINICAL RHEUMATOLOGY

Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review

(2016) J. R. Curtis et al.   JOURNAL OF RHEUMATOLOGY

Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence

(2016) Johan Dalén et al.   RHEUMATOLOGY INTERNATIONAL

Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis

(2016) Shonda A. Foster et al.   Journal of Managed Care & Specialty Pharmacy

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

(2016) D.S. Courvoisier et al.   EBioMedicine

The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study

(2015) Elisabeth Lie et al.   ANNALS OF THE RHEUMATIC DISEASES

Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers

(2015) Thierry Lequerré et al.   JOINT BONE SPINE

Impact of Biologic Agents With and Without Concomitant Methotrexate and at Reduced Doses in Older Rheumatoid Arthritis Patients

(2015) Jie Zhang et al.   ARTHRITIS CARE & RESEARCH

Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis

(2015) J. Harnett et al.   JOURNAL OF MEDICAL ECONOMICS

Meeting Abstracts - 27th Annual Meeting Expo

(2015)   Journal of Managed Care & Specialty Pharmacy

Targeting Medication Non-Adherence Behavior in Selected Autoimmune Diseases: A Systematic Approach to Digital Health Program Development

(2015) Trevor van Mierlo et al.   PLoS One

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network

(2014) J.M.P.A. van den Reek et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies

(2014) Shinya Hirabara et al.   CLINICAL RHEUMATOLOGY

Utilization and Adherence Patterns of Subcutaneously Administered Anti–Tumor Necrosis Factor Treatment Among Rheumatoid Arthritis Patients

(2014) Joseph Tkacz et al.   CLINICAL THERAPEUTICS

Longterm Retention Rate and Risk Factor for Discontinuation Due to Insufficient Efficacy and Adverse Events in Japanese Patients with Rheumatoid Arthritis Receiving Etanercept Therapy

(2014) H. Matsubara et al.   JOURNAL OF RHEUMATOLOGY

Longterm Followup of Rituximab Therapy in Patients with Rheumatoid Arthritis: Results from the Belgian MabThera in Rheumatoid Arthritis Registry

(2014) F. De Keyser et al.   JOURNAL OF RHEUMATOLOGY

Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis

(2014) A. Svedbom et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO

(2014) B. Glintborg et al.   RHEUMATOLOGY

Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

(2014) James Bluett et al.   RHEUMATOLOGY

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs

(2014) Huabin F Zhang et al.   ARTHRITIS RESEARCH & THERAPY

Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis

(2014) Fiorenzo Santoleri et al.   JOURNAL OF MEDICAL ECONOMICS

Documentation of off-label use of biologics in Rheumatoid Arthritis

(2013) Daniel E Furst et al.   ANNALS OF THE RHEUMATIC DISEASES

The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study

(2013) Karen Minde Fagerli et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry

(2013) Bente Glintborg et al.   ARTHRITIS AND RHEUMATISM

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

(2013) M. Esposito et al.   BRITISH JOURNAL OF DERMATOLOGY

Treatment Patterns and Health Care Costs for Patients With Psoriatic Arthritis on Biologic Therapy: A Retrospective Cohort Study

(2013) Baojin Zhu et al.   CLINICAL THERAPEUTICS

Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population

(2013) Maxine D. Fisher et al.   CURRENT MEDICAL RESEARCH AND OPINION

Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen

(2013) Joaquín Borrás-Blasco et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

(2013) Machaon Bonafede et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

(2013) J.M. Carrascosa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register

(2013) Flora McErlane et al.   RHEUMATOLOGY

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

(2013) Y Hishitani et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

(2013) Irini Flouri et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan

(2012) Benjamin Chastek et al.   ADVANCES IN THERAPY

Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings

(2012) Machaon Bonafede et al.   ADVANCES IN THERAPY

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry

(2012) Jeffrey D Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

(2012) Bente Glintborg et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis

(2012) Cheng-Tao Yang et al.   CLINICAL RHEUMATOLOGY

Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease

(2012) Amit Desai et al.   INFLAMMATORY BOWEL DISEASES

The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 – a retrospective analysis

(2012) Valerie Nell-Duxneuner et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population

(2012) Benjamin Chastek et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Longterm Retention of Tumor Necrosis Factor-  Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

(2012) F. IANNONE et al.   JOURNAL OF RHEUMATOLOGY

Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy

(2012) Elizabeth A. Brezinski et al.   PLoS One

Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costs

(2011) Chureen T. Carter et al.   ADVANCES IN THERAPY

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

(2011) H. C. Leffers et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

(2011) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis

(2011) Vito Di Lernia et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry

(2011) J. A. MARKENSON et al.   JOURNAL OF RHEUMATOLOGY

Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data

(2011) Soo-Kyung Cho et al.   RHEUMATOLOGY INTERNATIONAL

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry

(2010) B. Glintborg et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry

(2010) Bente Glintborg et al.   ARTHRITIS AND RHEUMATISM

Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen

(2010) Joaquín Borrás-Blasco et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Adherence to adalimumab therapy in Crohnʼs disease: A French multicenter experience

(2010) Vincent Billioud et al.   INFLAMMATORY BOWEL DISEASES

Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database

(2010) M. P. Staples et al.   RHEUMATOLOGY

Sustained Clinical Response in Psoriatic Arthritis Patients Treated with Anti-TNF Agents: A 5-year Open-Label Observational Cohort Study

(2010) Ioanna Saougou et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis

(2010) Pengxiang Li et al.   VALUE IN HEALTH

Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register

(2010) L. E. Kristensen et al.   ARTHRITIS CARE & RESEARCH

Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity

(2010) Bert Vander Cruyssen et al.   ARTHRITIS RESEARCH & THERAPY

Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients

(2009) Sunanda V. Kane et al.   ADVANCES IN THERAPY

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

(2009) Sophie Martin Du Pan et al.   ARTHRITIS AND RHEUMATISM

Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costs

(2009) Bijan J. Borah et al.   CURRENT MEDICAL RESEARCH AND OPINION

Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohnʼs disease†

(2009) Daniel J. Stein et al.   INFLAMMATORY BOWEL DISEASES

Changing Patterns of Tumor Necrosis Factor Inhibitor Use in 9074 Patients with Rheumatoid Arthritis

(2009) Y. YAZICI et al.   JOURNAL OF RHEUMATOLOGY

Six and 12 Weeks Treatment Response Predicts Continuation of Tumor Necrosis Factor Blockade in Rheumatoid Arthritis: An Observational Cohort Study from Southern Sweden

(2009) A. GULFE et al.   JOURNAL OF RHEUMATOLOGY

Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register

(2009) Amr A Saad et al.   ARTHRITIS RESEARCH & THERAPY

Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort

(2008) Jeffrey D. Greenberg et al.   AMERICAN JOURNAL OF MEDICINE

Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry

(2008) M L Hetland et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis

(2008) P Tynjala et al.   ANNALS OF THE RHEUMATIC DISEASES

Compliance with biologic therapies for rheumatoid arthritis: Do patient out-of-pocket payments matter?

(2008) S. Curkendall et al.   ARTHRITIS AND RHEUMATISM

Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis

(2008) Boxiong Tang et al.   CLINICAL THERAPEUTICS

Medication Adherence of Patients with Selected Rheumatic Conditions: A Systematic Review of the Literature

(2008) Leslie R. Harrold et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Medication Compliance and Persistence: Terminology and Definitions

(2007) Joyce A. Cramer et al.   VALUE IN HEALTH